Telix and ITM agree $1.65bn radiopharmaceutical merger

Telix Pharmaceuticals has agreed to acquire ITM in a major radiopharmaceutical transaction valued at $1.65 billion upfront, with up to a further $700 million linked to regulatory and commercial milestones.

The combination brings together Telix's oncology-focused radiopharmaceutical portfolio with ITM's isotope production infrastructure and therapeutic development capabilities.

The transaction is intended to create a larger vertically integrated radiopharmaceutical company with capabilities spanning isotope supply, drug development, manufacturing and commercialisation.

Field	Content
Alert Type	Deal
Companies	Telix Pharmaceuticals; ITM
Deal Type	Acquisition
Asset or Company	ITM
Therapy Area(s)	Oncology; nuclear medicine
Technology or Modality	Radiopharmaceuticals; radioligand therapy; medical isotopes
Deal Value	US$1.65 billion upfront on a cash-free/debt-free basis, plus up to US$700 million in contingent regulatory and commercial milestone payments
Geography	Global
What Happened	Telix agreed to acquire 100% of ITM in a transaction valued at US$1.65 billion upfront, with additional contingent payments linked to ITM-11.
Why It Matters	The transaction combines a commercial and clinical radiopharmaceutical portfolio with major isotope-production capabilities, increasing scale across the radiopharma value chain.
Supporting Context	ITM has established isotope-production infrastructure and a pipeline of radiopharmaceutical therapies, while Telix has built a growing portfolio of diagnostic and therapeutic nuclear-medicine products.
Strategic Rationale	Telix gains greater control over isotope supply, manufacturing and therapeutic development while expanding its oncology pipeline and global radiopharmaceutical infrastructure.
Potential Impact	The combined business could improve isotope security, accelerate development of new radioligand therapies and strengthen competition in the rapidly expanding radiopharmaceutical market.
Key Takeaway	Telix is acquiring ITM for US$1.65 billion upfront in a major transaction designed to create a vertically integrated global radiopharmaceutical company.
What to Watch	Regulatory approvals, transaction completion, integration of isotope-production operations and progress of ITM-11 against its contingent milestones.
Primary Source	Telix Pharmaceuticals
Relevant Date	21 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com